February 22, 2021 – Philadelphia, PA – We are pleased to announce that James Chen will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Senior Director of Quality.

Mr. James Chen will be leading WuXi ATU China Quality organization and working closely with business leaders in US and China to continuously improve our quality system and processes in order to support the rapid growth of the business. James has more than 18 years working experience in the pharmaceutical industry. Prior to joining WuXi ATU, James held several roles in R&D, Regulatory, Quality and Compliance at Roche, United States Pharmacopeia and other pharmaceutical companies and has a proven track record of promoting quality culture, establishing quality organizations, leading cross-functional and cross region projects and leading successful regulatory inspections.  James is also actively supporting and participating in several pharmaceutical industry associations, such as R&D-based Pharmaceutical Association Committee (RDPAC), International Society for Pharmaceutical Engineering (ISPE) and International Pharmaceutical Excipients Committee (IPEC).

James graduated with a bachelor’s degree of Pharmacy from Medical Center of Fudan University and acquired his master degree of Pharmaceutical Technology at King’s College, London.

We are excited to welcome James to WuXi Advanced Therapies!


About WuXi Advanced Therapies (ATU)
As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit www.advancedtherapies.com


Media Contact:
Min Park
Global Head of Marketing
WuXi Advanced Therapies